Tuesday, July 21, 2026
🇺🇸 FDA

pharma · Knee Osteoarthritis · Hypoplastic Left Heart Syndrome · RGBP

Regeneron Ireland Designated

Regeneron Ireland Designated Activity Company (DAC)

Regeneron Ireland Designated patent portfolio — 50 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

LA MESA, CA, IE HQ
Public company Type
RGBP · NYSE Ticker
Company details
Status
Public
HQ
LA MESA, CA, IE
Programs
0
Drugs
56
Patents
50
Drug pipeline Patents News & analysis
Intelligence · Patents

Regeneron Ireland Designated patents

50 pharmaceutical patents indexed for Regeneron Ireland Designated. 1 expire within 24 months.

Regeneron Ireland Designated has 50 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 1 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

50 patents

Patent portfolio

Page 1 of 2

  1. US 12150956

    Trace element compositions, methods of making and use

    Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12150957

    Trace element compositions, methods of making and use

    Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11998565

    Trace element compositions, methods of making and use

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11975022

    Trace element compositions, methods of making and use

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11786548

    Trace element compositions, methods of making and use

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11673898

    Substituted inhibitors of menin-MLL and methods of use

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11591579

    Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11478502

    Methods and compositions for administration of iron

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11433091

    Methods and compositions for administration of iron

    Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11413296

    Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11396647

    Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

    Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11369566

    Controlled release antimicrobial compositions and methods for the treatment of otic disorders

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11364260

    Methods and compositions for administration of iron

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11311541

    Treatment of GVHD

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11197822

    Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11118167

    Enzyme-mediated depletion of adenosine and/or methylthioadenosine

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11040091

    Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10781218

    Substituted inhibitors of menin-MLL and methods of use

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10583180

    Method for treating adenosine deaminase severe combined imunodeficiency

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10251894

    Anticonvulsant activity of steroids

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10174041

    Methods and compositions for inhibiting the interaction of menin with MLL proteins

    Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10077271

    Methods and compositions for inhibiting the interaction of menin with MLL proteins

    Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9987261

    Substituted diazaspiroalkanes as androgen receptor modulators

    Expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9925158

    Enterically coated cysteamine, cystamine and derivatives thereof

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9925157

    Enterically coated cysteamine, cystamine and derivatives thereof

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9925156

    Enterically coated cysteamine, cystamine and derivatives thereof

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9631001

    Peptide antagonists of the vasopressin-2 receptor

    Expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9603796

    Controlled release antimicrobial compositions and methods for the treatment of otic disorders

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9580427

    Kinase inhibitors

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9388159

    Substituted diazaspiroalkanes as androgen receptor modulators

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9233068

    Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9205048

    Controlled release antimicrobial compositions and methods for the treatment of otic disorders

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9198882

    Enterically coated cysteamine, cystamine and derivatives thereof

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9192590

    Enterically coated cysteamine, cystamine and derivatives thereof

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9126941

    Treatment of hyperproliferative disorders with diarylhydantoin compounds

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9119863

    Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9018210

    Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation

    Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8975243

    Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Mar 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8802689

    Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

    Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8679545

    Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8497258

    Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8445507

    Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

    Expires Mon May 16 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8324192

    Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8318817

    Controlled release antimicrobial compositions and methods for the treatment of otic disorders

    Expires Mon Nov 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8183274

    Treatment of hyperproliferative disorders with diarylhydantoin compounds

    Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8026284

    Enterically coated cystamine, cysteamine and derivatives thereof

    Expires Mon Sep 22 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7754230

    Methods and related compositions for reduction of fat

    Expires Mon Jul 08 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7709517

    Diarylhydantoin compounds

    Expires Mon Apr 29 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

50 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

1 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.